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Abstract
Background. The blood–brain and blood–tumor barriers (BBB and BTB), which restrict the entry of most drugs
into the brain and tumor, respectively, are a significant challenge in the treatment of glioblastoma. Laser interstitial thermal therapy (LITT) is a minimally invasive surgical technique increasingly used clinically for tumor cell
ablation. Recent evidence suggests that LITT might locally disrupt BBB integrity, creating a potential therapeutic
window of opportunity to deliver otherwise brain-impermeant agents.
Methods. We established a LITT mouse model to test if laser therapy can increase BBB/BTB permeability in vivo.
Mice underwent orthotopic glioblastoma tumor implantation followed by LITT in combination with BBB tracers or
the anticancer drug doxorubicin. BBB/BTB permeability was measured using fluorimetry, microscopy, and immunofluorescence. An in vitro endothelial cell model was also used to corroborate findings.
Results. LITT substantially disrupted the BBB and BTB locally, with increased permeability up to 30 days after the
intervention. Remarkably, molecules as large as human immunoglobulin extravasated through blood vessels and
permeated laser-treated brain tissue and tumors. Mechanistically, LITT decreased tight junction integrity and increased brain endothelial cell transcytosis. Treatment of mice bearing glioblastoma tumors with LITT and adjuvant
doxorubicin, which is typically brain-impermeant, significantly increased animal survival.
Conclusions. Together, these results suggest that LITT can locally disrupt the BBB and BTB, enabling the targeted
delivery of systemic therapies, including, potentially, antibody-based agents.

Key Points
• Laser therapy increases BBB and BTB permeability up to 30 days posttreatment and
enables brain entry of large-molecular-weight moieties.
• Laser therapy increases BBB and BTB permeability by disrupting endothelial cell tight
junctions and increasing transcytosis.
• In a preclinical mouse model, laser ablation with adjuvant chemotherapy significantly
improved animal survival.
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This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
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Importance of the Study
The blood–brain and blood–tumor barriers (BBB and BTB),
which restrict the entry of therapeutic drugs to the brain,
are a significant challenge in the treatment of glioblastoma. We established a laser interstitial thermal therapy
(LITT) mouse model and tested if LITT can increase BBB
and BTB permeability. We demonstrated that LITT disrupts
the BBB and BTB over a sustained duration and enables

local tumor access of an anticancer drug in an animal glioblastoma model. Taken together, this work provides the
foundation for a novel laser-based approach to locally
treating malignant tumors in the brain.

Materials and Methods
Cell Culture
Glioma 261 (GL261)12 cells (a generous gift from Dr
Gavin Dunn, Washington University, St. Louis), bEnd.3
(ATCC CRL-2299), and 293LE cells were cultured in
DMEM (Sigma) with 10% fetal bovine serum (ThermoFischer Scientific) and 1:100 penicillin/streptomycin.
MGG8 human glioblastoma cells (a generous gift from
Drs Hiroaki Wakimoto and Daniel Cahill, Harvard Medical
School) were cultured as spheres in Neurobasal medium
supplemented with N2, B27, and nonessential amino
acids (Thermo-Fischer Scientific) plus EGF and bFGF
(Peprotech, 20 ng/mL).13 All cells were incubated at 37°C
with 5% (vol/vol) CO2. Viral transduction was performed
as described.14

Laser Interstitial Thermal Therapy
All animal experiments were in accordance with a protocol
approved by the Animal Studies Committee at Washington
University and compliant with the recommendations of
the Guide for the Care and Use of Laboratory Animals
(NIH). A stereotactic apparatus was used to target coordinates 0.25 mm rostral to bregma, 2 mm lateral, and 2 mm
deep. Laser therapy was delivered using a Dornier Medilas
Fibertom 8100 at 2 W power on continuous mode to deliver an Nd-YAG laser at 1064 nm through a 600 µm fiber
optic cable. The temperature was measured with a 400 nm
thermocouple 1 mm rostral to the laser fiber. The laser was
manually switched on and off to maintain the desired temperature ranges at 43°C. Laser-treated mice were injected
with 30 mg/kg of phenytoin intraperitoneally for seizure
prophylaxis.

Orthotopic Tumor Implantation
Tumor cell injections were performed as described.15
About 50 000 cells in 3 μL of Matrigel (Corning) or
phosphate-buffered saline were stereotactically injected
into the right somatosensory cortex of 6-week-old mice
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Glioblastoma is the most common malignant primary
brain tumor, which is characterized by an aggressive
natural history and poor prognosis. Although advances
have been made along multiple therapeutic fronts, median survival for this disease remains about 15 months,
with a 5-year survival of less than 10%.1 Other than the
standard-of-care drug, temozolomide, most systemic
chemotherapeutics have been unsuccessful in large part
from the blood–brain barrier (BBB) restricting the delivery
of anticancer drugs to tumor-infiltrated brain.2 Blood–
tumor barrier (BTB) permeability is more complex, as
angiogenesis in glioblastoma leads to the formation of
abnormal tumor microvessels, which exhibit limited and
heterogeneous permeability.3 Additionally, established
microvessels feeding the infiltrating edge of the tumor are
as impermeable as the normal BBB.4 Thus, there is an urgent need to identify new approaches to bypass the BBB
and BTB to deliver therapeutic drugs to glioblastomas and
other diseases of the CNS.
Several strategies have been developed to increase delivery of therapeutic compounds to brain tumors, including
modification of drug structure or use of carrier molecules,
direct delivery to the tissue, chemical disruption of the
BBB, and local physical disruption of the BBB.5–7 Local disruption of the BBB in regions of pathology carries certain
advantages, including flexibility of combinations with different systemically delivered drugs while mitigating drug
delivery and BBB leakiness in the unaffected brain. A recent study suggested that laser interstitial thermal therapy
(LITT) could disrupt the local peritumoral BBB in tumor
patients.8 LITT is a minimally invasive ablative technique
that has shown promise in the treatment of brain tumors,
including glioblastoma, other gliomas, and brain metastases.9–11 The tissue surrounding the laser absorbs emitted
photons, causing controlled local hyperthermia and tumor
cell death. At the periphery of the laser-treated zone, LITT
increases contrast enhancement along with other MR
markers of BBB disruption in human patients.8 However,
there is little direct evidence for LITT-induced changes in
BBB and BTB permeability, and fundamental characteristics of the LITT effect on BBB/BTB permeability such as molecular size threshold and mechanism of action remain to
be explored.
To address these questions, we developed a mouse
model of LITT and show that laser treatment increases BBB
and BTB permeability over an extended period following
treatment. We also identify mechanisms underlying these
changes in BBB and BTB permeability. Finally, we take
advantage of this property of laser treatment to augment

therapeutic agents and molecules as large as antibodies
to enter the central nervous system (CNS). Furthermore,
our preclinical mouse experiments provide proof of the
concept that laser-induced BBB/BTB disruption combined
with an anticancer drug can increase survival in glioblastoma tumor-bearing mice. These results have implications
for the treatment of various CNS tumors.

Salehi et al. LITT increases BBB and BTB permeability

In Vivo BBB and BTB Permeability Assays

Histopathology and Immunofluorescence
For histology, brain sections were stained with hematoxylin and eosin. For immunofluorescence, frozen sections
or confluent bEnd.3 cells were stained with primary antibodies followed by incubation with corresponding Alexa
fluorophore-conjugated secondary antibodies (ThermoFisher Scientific). Immunofluorescence images were analyzed via corrected total fluorescence on ImageJ (NIH; see
Supplementary Materials).

Doxorubicin Permeability and Quantification
Briefly, doxorubicin (Sigma-Aldrich, 16 mg/kg in sterile
water) was injected intravenously into mice. Mice were
anesthetized and perfused and treated brain regions harvested. Brain homogenates were used to measure doxorubicin concentration by fluorometry.17 For bioluminescence
live imaging (BLI) and survival experiments, 12 mg/kg
of doxorubicin was used for the first dose and 8 mg/kg
of doxorubicin for the second dose (see Supplementary
Materials).

Statistics
All experiments including images are representative of
results from 3 independent experiments unless otherwise stated and were quantified in a blinded fashion. In
animal experiments, mice were randomized to different
treatment arms. Statistical analyses were performed
with GraphPad Prism 8.0.2. The unpaired Student’s t-test
was used for comparisons in experiments with only 2
groups. In experiments with more than 2 comparison
groups, ANOVA was performed with Bonferroni post-hoc
test for pairwise comparisons. P < .05 was considered
significant.

Establishing a Mouse Model of LITT
We established a mouse model to stereotactically deliver laser treatment into either the mouse somatosensory cortex or an orthotopically implanted brain tumor
(Figure 1A). To model glioblastoma, GL261 cells were
stereotactically injected into the somatosensory cortex
of C57BL/6J mice and then treated with LITT 7–10 days
later (Figure 1B–E). Laser treatment was delivered for up
to 3 min while a co-inserted thermocouple sensor 1 mm
from the laser fiber was used to maintain tissue temperatures at least 43°C (Supplementary Figure S1) to model
laser therapy delivered in humans. Temperatures at the
laser-treated core of the tumor reached more than 50°C, resulting in irreversible cell death (Figure 1E; Supp1ementary
Figures S1 and S2). Magnetic resonance imaging (MRI)
was performed pre- and post-LITT on tumor-bearing
mice, which demonstrated reproducible targeting of
brain tumors (Figure 1B). Post-LITT MRI of tumor-bearing
mice showed a central area of heterogeneous T2W
hypointensity, consistent with coagulative necrosis and
blood products as well as a halo of T2W hyperintensity,
indicating edema (Figure 1B), similar to the imaging characteristics described in human LITT.18 To demonstrate that
LITT can ablate tumor cells in vivo, we stereotactically injected luciferase-expressing GL261 intracranially in mice to
monitor tumor burden by BLI. Tumor burden was significantly lower in laser- versus sham-treated mice 3 days after
treatment (Figure 1C and D). Accordingly, histopathological analysis of laser-treated tumors showed loss of nuclei
and increased eosin staining in the laser core, consistent
with tumor cell necrosis.19 Transmission electron microscopy of the native brain treated with LITT showed similar results. Three days after laser treatment, we observed
widespread necrotic tissue injury, loss of cellular adhesion,
and the presence of red blood cells from vessel destruction
in the core. In a concentric area of the brain adjacent to and
outside of the necrotic laser core, we observed relatively
preserved blood vessels and normal surrounding neuropil
(Supplementary Figure S3).

BBB and BTB Permeability Are Increased by
Laser Treatment
To determine if LITT directly affects BBB permeability in
mice, we intravenously injected fluorescein at several
time points following laser or sham treatment in native
brain tissue and then harvested treated brain areas for
analysis (Figure 2A). Relative BBB permeability, as measured by brain fluorescein accumulation, substantially
increased within the first week post-LITT before gradually decreasing (Figure 2B). LITT-treated hemispheres
demonstrated a significantly greater degree of fluorescein permeability compared to sham-treated hemispheres and the cerebellum, a distant site in LITT-treated
mice, indicating treatment and location-specific BBB effect (Figure 2C). Although fluorescein accumulation in
laser-treated brains was visibly evident by fluorescence
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Fluorescein permeability assay was performed as
described.16 Briefly, mice were injected with an
intraperitoneal dose of sodium fluorescein solution
(Sigma-Aldrich). Mice were euthanized, and blood and
brain tissue collected, with the harvesting of an approximately 3 mm × 3 mm × 3 mm cube of fluoresceinpermeable and corresponding control brain area
identified via monocular microscopy (Amscope). For
dextran/IgG permeability, 10 kDa and 70 kDa dextran
(Thermo-Fischer Scientific) or human IgG (SigmaAldrich) were injected intravenously (retro-orbital) in
mice (see Supplementary Materials).

Results

Neuro-Oncology
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(C57BL/6J for GL261, NOD-SCIDγ for MGG8) at coordinates 0.25 mm rostral to bregma, 2 mm lateral, and
2 mm deep using a 10 µL Hamilton syringe. Tumors were
allowed to grow for 7–10 days prior to subsequent experimentation (specified in Figure Legends). To monitor
tumor burden, live bioluminescence imaging was performed as described.15
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Figure 1. Establishment of a LITT mouse model. (A) Schematic depiction of the LITT delivery system in mice. The laser fiber (right arrow) is positioned 1 mm caudal to the thermo-sensor (left arrow). (B) Animals stereotactically implanted with GL261 tumor cells were subjected to MRI 7 days
later. Representative T2-weighted MR images of 2 mice before and 24 h after LITT are shown. Tumor (dashed circle) and LITT-treated area (black
arrow) are highlighted (n = 3 for each). Scale bar = 2 mm. (C) Animals stereotactically implanted with luciferase-expressing GL261 tumor cells were
treated 8 days later with LITT or sham. (D) Tumor volume was quantified by BLI 3 days posttreatment. LITT-treated animals had significantly lower
tumor burden compared to sham (n = 5 for each condition, unpaired t-test, *P < .01). (E) Representative H&E stained sections of sham (top) and
laser-treated (bottom) mouse brains are shown (n = 3 for each condition). Loss of nuclear hematoxylin staining and enhanced eosin staining are
observed in the necrotic laser core. Scale bar = 500 µm, 100 µm.
  

imaging on post-LITT days 14 and 30, the increase in
quantitative fluorescein tracer within the hemisphere
was not significant at these time points, likely due to
decreased assay sensitivity for detecting more minute
differences in fluorescein accumulation (Figure 2A and
B). We therefore adopted a complementary, more sensitive, immunofluorescence-based approach to determine
if laser-induced BBB permeability extends beyond the
7 days identified by the fluorescein assay. Using intravenous 10 kDa dextran as a second tracer for BBB integrity,
we observed a significant increase in BBB permeability
on post-LITT day 30 (Figure 2D and E).
Similarly, to determine the integrity of the BTB, quantitative fluorescein permeability assays were performed in
mice bearing GL261 tumors following LITT to the tumor
(Figure 2F and G). Laser treatment of tumors significantly
increased fluorescein tracer infiltration in tumor-bearing
hemispheres compared to that of untreated control tumors
for at least 2 weeks post-LITT (Figure 2F). Laser-treated
tumors demonstrated a significantly greater degree of

fluorescein permeability compared to sham-treated tumors and normal control brains (Figure 2G).

LITT Increases BBB and BTB Permeability to
Large Molecules
Our results demonstrate that local BBB and BTB integrity is decreased in LITT-treated brain and brain tumors,
raising the possibility that larger molecular weight moieties might also be capable of permeating the BBB and
BTB following LITT. We therefore intravenously injected
70 kDa dextran in mice 3 days following laser or sham
treatment (Figure 3A). As a positive control, an intravenous injection was confirmed by the detection of dextran
in the liver (Supplementary Figure S4). We observed increased 70 kDa dextran infiltration particularly outside of
the laser core, in the laser penumbra, a concentric region
adjacent to and surrounding the core, which was not evident in the sham-treated brain (Figure 3A). Quantification
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Figure 2. LITT increases BBB and BTB permeability in vivo. (A) Representative white light and fluorescence images of mouse brains harvested
on the indicated days after intravenous fluorescein injection (n = 3 for each condition). LITT was performed in the right somatosensory cortex.
Control = unmanipulated brain. Scale bar = 5 mm. (B) Animals treated as in A were assessed for tissue fluorescein uptake (normalized to control
brains) on indicated post-LITT days. Control = 1 (dotted line). Data represent mean ± SEM. Laser increased BBB permeability compared to control
(n = 3 for each condition, ANOVA, *P < .05, **P < .01, ***P < .001). (C) Relative BBB permeability was measured as in B on post-laser day 3 in indicated brain regions. LITT increased BBB permeability in the treated forebrain hemisphere, but not in the cerebellum (CBL) of the same brain or
sham treatment (insertion of optical fiber) (n = 3 for each condition, ANOVA, *P < .01). (D) Animals treated with laser were injected intravenously
with 10 kDa dextran on post-LITT day 30, and brains processed for immunofluorescence on free-floating 50 µm sections to assess dextran penetration. Representative images are shown (n = 3 for each condition). Scale bar = 50 µm. (E) Brain permeability of 10 kDa dextran was quantified by
the mean pixel intensity of fluorescence divided by area (µm2). Data represent mean ± SEM (n = 3 for each condition, unpaired t-test, *P < .01). (F)
Animals were orthotopically implanted with GL261 tumor cells, and laser treatment to the tumor performed 7 days later. Relative BTB permeability
(normalized to control brain) was assessed by quantification of tissue fluorescein uptake on indicated post-LITT days. Control = 1 (dotted line). LITT
increased BTB permeability compared to control (n = 3 for each condition, ANOVA, *P < .01, **P < .001). (G) Relative BTB permeability was measured as in (F) on post-laser day 3 following LITT (treated) or sham treatment. The normal brain represents a contralateral forebrain hemisphere with
no tumor and not treated with laser. Laser treatment increased BBB permeability in the tumor-bearing hemisphere compared to sham treatment
and contralateral hemisphere (n = 3 for each condition, ANOVA, *P < .001).
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Figure 3. LITT increases BBB and BTB permeability to large molecules. (A) Animals treated with LITT were injected intravenously with 70 kDa dextran
on post-laser day 3, and brains harvested and processed for immunofluorescence to assess dextran penetration. Representative images are shown
(n = 3 for each condition). Scale bar = 100 µm; scale bar for magnified images = 300 µm. (B) Mice with stereotactically injected RFP-expressing GL261
cells were treated with LITT 10 days after implantation and injected intravenously with 70 kDa dextran on post-LITT day 3. Brains were processed as in
A. Representative images are shown (n = 3 for each condition). (C) Mice treated with LITT as in A were injected intravenously with human IgG on postlaser day 3, and brains processed to assess IgG tissue penetration. Representative images are shown (n = 3 for each condition). (D) Tumor-bearing mice
as in B were treated with LITT 10 days after implantation and injected intravenously with human IgG on post-LITT day 3. Brains were processed as in
C. Representative images are shown (n = 3 for each condition). (E) Brain permeability of 70 kDa dextran and human IgG in LITT- and sham-treated brain
was quantified by mean pixel intensity of fluorescence divided by area (µm2). Data represent mean ± SEM. LITT significantly increased penetration of
70 kDa dextran and human IgG compared to sham (n = 3 for each condition, t-test, *P < .01, **P < .001). (F) Brain tumor permeability of 70 kDa dextran
and human IgG in laser- and sham-treated brain was quantified by mean pixel intensity of fluorescence divided by area (µm2). Data represent mean ±
SEM. Laser treatment significantly increased tumor penetration of 70 kDa dextran and human IgG (n = 3 for each condition, t-test, *P < .05, **P < .01). (G)
NOD-SCIDγ mice were stereotactically injected with MGG8 human glioblastoma cells and subjected to sham or laser treatment 10 days after implantation. Animals were injected intravenously with human IgG on post-laser day 3, and brains processed with immunofluorescence to assess IgG tissue
penetration. Representative images are shown (n = 2 for each condition). DAPI = nuclear stain. Scale bar = 100 μm. Magnified image scale bar = 400 μm.
(H) Tissue was processed as in D and BTB permeability quantified as in F for MGG8 tumor-bearing mice. Data represent mean ± SEM. Laser treatment
significantly increased tumor penetration of human IgG (n = 3 for each condition, t-test, **P < .002).
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We next focused on the laser penumbra, which appeared
not to harbor obvious cellular disruption by histology
(Figure 1E; Supplementary Figure S3) but demonstrated
tissue infiltration of BBB permeability tracers (Figure 3),
to understand the mechanisms by which LITT increases
BBB permeability. First, we investigated if LITT disrupts the
functional integrity of brain endothelial cell tight junctions
in vivo, an important mechanism of BBB maintenance.21
Mice treated with LITT were intravenously injected with
horseradish peroxidase (HRP), and electron microscopy in
the laser penumbra was performed to evaluate tight junction integrity (Figure 4A). Whereas sham-treated brains
demonstrated intact tight junctions that halted luminal
HRP at tight junction sealing strands, LITT-treated brains
showed tight junction aberrancies with separated sealing

LITT Promotes Endothelial Cell Transcytosis
Recent reports indicate that active inhibition of endothelial cell transcytosis is another means of restricting
BBB permeability under physiological conditions and
can become dysregulated after pathological insults.23,24
Mice treated with LITT were intravenously injected with
HRP, and brains harvested for electron microscopic analysis of HRP-containing vesicles in brain endothelial cells
(Figure 5). Consistent with previous reports, endothelial cells in sham-treated brain demonstrated a low basal
rate of transcytosis (Figure 5A).25 Strikingly, brain endothelial cells in the laser penumbra in LITT-treated mice
demonstrated an increase in HRP-filled endocytic vesicles
(Figure 5A). Mean vesicular density in endothelial cells
within the laser penumbra was increased 2- to 3-fold compared to sham treatment (Figure 5C), suggesting endothelial cell transcytosis also contributes to the laser-induced
elevation of BBB permeability.

Laser-Mediated Drug Delivery to the Brain
Increases Animal Survival
Having established that LITT increases local BBB/BTB
permeability, we hypothesized that laser treatment might
facilitate local drug delivery to brain tumors for therapeutic benefit. We tested if laser treatment could increase
brain penetration of the chemotherapeutic agent doxorubicin because (1) doxorubicin is an effective antiglioblastoma agent in vitro26 but is known to be BBB
impermeant27 and (2) a current clinical trial is testing the
efficacy of LITT plus doxorubicin for recurrent glioblastoma (clinicaltrials.gov, NCT01851733). Mice injected
with GL261 tumors were treated with laser or sham treatment after 8 days and then intravenously injected with
doxorubicin 3 days after probe insertion. Brains were assessed for doxorubicin penetration using a fluorescencebased assay (Figure 6A and B). Whereas sham-treated
mice showed little evidence of parenchymal doxorubicin infiltration, LITT-treated mice showed substantial
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LITT Disrupts Tight Junction Integrity In Vivo
and In Vitro

strands and leakage of HRP toward the abluminal side in
the laser penumbra (Figure 4A). We hypothesized that LITT
might perturb the tight junction structure by altering the
expression of key tight junction proteins. Brain endothelial
cells express claudin V, a transmembrane protein concentrated in tight junctions and whose depletion is associated
with BBB disruption in mice in vivo and human endothelial cells in vitro.22 Laser treatment of the brain triggered
a more punctate pattern and a decrease in overall intensity of claudin V staining in endothelial cells of the laser
penumbra (Figure 4B and C). To test if thermal treatment
directly causes a decrease in claudin V protein, human
endothelial cells (bEnd.3) cultured in vitro were heated to
43°C for 90 min followed by incubation at 37°C (Figure 4D
and E). One day after thermal treatment, bEnd.3 cells
showed a dramatic decrease in claudin V protein levels at
the plasma membrane (Figure 4D and E) with little effect
on cell viability (data not shown), suggesting a direct effect
of thermal energy on tight junction dysfunction.

Neuro-Oncology
Advances

of dextran fluorescence intensity in brain parenchyma
indicated a significant increase in laser-induced BBB permeability (Figure 3E). We then investigated whether laserinduced permeability could allow even larger molecules,
such as antibodies, to penetrate the BBB. Human IgG,
which is approximately 150 kDa, was intravenously injected in mice 3 days after laser treatment. Immunostaining
of human IgG in laser-treated mouse brain also demonstrated widespread infiltration predominantly in the
laser penumbra with little IgG infiltration in sham-treated
brain (Figure 3C and E). In parallel, we tested if LITT increases BTB permeability to large molecules. Analysis of
LITT-treated GL261 tumor-bearing mice demonstrated increased 70 kDa dextran and human IgG permeability in
brain tumors (Figure 3B, D, and F). As with laser-treated
brain, an inspection of the spatial pattern of laser-induced
BTB permeability revealed little tumor penetration of both
large-molecular-weight tracers in the necrotic core of lasertreated tumors and extensive infiltration in the surrounding
laser penumbra within tumor regions (Supplementary
Figure S5).
We confirmed that LITT increases BTB permeability in an
additional mouse model of glioblastoma, using a human
patient-derived glioblastoma sphere line (MGG8) implanted intracranially in NOD-SCIDγ mice (Figure 3G).13,20
Quantification of human IgG fluorescence intensity in
brain parenchyma indicated a significant increase in
laser-induced BTB permeability (Figure 3H). To verify that
intravenous human IgG penetrates LITT-treated tumor parenchyma and does not merely reside in blood vessels,
we co-stained for human IgG and the endothelial marker
CD31 in LITT-treated tumors. Substantial extravasation of
IgG molecules was observed outside of blood vessels in
LITT-treated tumors compared to that of sham treatment
(Supplementary Figure S6A). Quantification of the IgG
permeability index indicated a significant increase in the
delivery of IgG to tumor parenchyma outside of blood
vessels following laser treatment (Supplementary Figure
S6B). Together, these observations indicate that LITT can
increase BBB and BTB permeability to small- and largemolecular-weight moieties predominantly in tissue regions
surrounding the laser core.
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Figure 4. LITT disrupts brain endothelial cell tight junctions. (A) Representative transmission electron microscopy images are shown following intravenous HRP injection in sham and laser-treated brains (n = 3 for each condition). Intact tight junctions (arrows) are observed in the control brain whereas
tight junction aberrancies (arrows) are seen in the laser penumbra of laser-treated brain. L, blood vessel lumen; EC, endothelial cell. Scale bar = 100 nm. (B)
Brains of animals treated with LITT or sham treatment were processed on post-LITT day 3 for claudin V immunofluorescence. CD31, endothelial cell marker.
Representative images are shown (n = 3 for each condition). Scale bar = 50 µm. (C) The integrity of brain endothelial cell tight junctions in mice treated as in
B was quantified by area of claudin V immunostaining divided by the area of blood vessels (CD31 immunostaining, µm2). Data represent mean ± SEM. LITT
significantly decreased tight junction integrity compared to sham (n = 3 for each condition, t-test, *P < .0001). (D) Brain endothelial cells (bEnd.3) were cultured, and claudin V immunofluorescence performed after exposure to heat (43°C) for 90 min. Representative images are shown (n = 3 for each condition).
Scale bar = 50 µm. (E) The integrity of tight junctions in brain endothelial cells treated as in D was quantified by area of claudin V immunostaining divided by
cell count. Data represent mean ± SEM. Heat significantly decreased tight junction integrity compared to control (n = 3 for each condition, t-test, *P < .01).
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Figure 5. LITT increases endothelial cell transcytosis. (a) Representative transmission electron microscopy images are shown following intravenous HRP injection as in Figure 4A in sham and laser-treated brain on post-laser day 3 (n = 3 for each condition). HRP-filled vesicles within endothelial cells are highlighted (arrows). Scale bar = 100 nm. (B and C) Data represent mean ± SEM. Quantification of vesicular density (vesicles per μm)
per length of luminal (B) and abluminal (C) membrane shows increased transcytosis in brain endothelial cells of laser-treated brain compared to
sham-treated brain (n = 3 for each condition, 20 capillaries per animal, t-test, *P < .0001).
  

accumulation of brain tissue doxorubicin, indicating that
laser treatment increases local BBB permeability to enable doxorubicin entry (Figure 6A and B).
We thus tested the hypothesis that LITT in combination with doxorubicin is therapeutically superior to either
intervention alone in a preclinical model of glioblastoma
(Figure 6C). C57BL/6J mice were intracranially injected
with luciferase-expressing GL261 cells. After 8 days, animals were treated with laser or sham surgery to the tumor
followed by dosing with intravenous doxorubicin or vehicle. BLI was performed to monitor tumor burden on all
animals before and after treatments to ensure approximately equivalent initial tumor burden and to monitor subsequent therapeutic effects (Figure 6D and E). Although
doxorubicin alone had no effect on tumor progression in
mice, the combination of LITT plus doxorubicin significantly decreased tumor progression compared to control
or doxorubicin alone (Figure 6E). A larger cohort of brain
tumor-bearing animals treated in a similar manner were
monitored for neurological deficit-free survival. Whereas
tumor-bearing mice treated with laser demonstrated

increased survival compared to control or doxorubicintreated mice, mice treated with LITT plus doxorubicin
showed significantly prolonged survival compared to mice
in all other conditions including laser alone (Figure 6F).
LITT plus doxorubicin (median survival 36 days) increased
median survival by 71% compared to control treatment
(median survival 21 days).

Discussion
There is accumulating interest in LITT to treat brain pathologies due to its minimally invasive approach and associated faster recovery.9–11 Despite its increased clinical
use over the past decade, there is little understanding of
the biological effects of LITT on both tumor and the surrounding brain. To address this, we developed a mouse
model of LITT. Our data show that LITT enables local
delivery of small- and large-molecular-weight agents
through the BBB and BTB over an extended period. While
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Figure 6. LITT enhances therapeutic drug delivery to the brain. (A) Mice were subjected to sham or laser treatment and were injected intravenously with
doxorubicin (doxo) (16 mg/kg) on post-laser day 3. Three hours later, brains were harvested and imaged via white light or fluorescence for doxo signal. (B)
Brains from mice treated as in A were harvested, and brain homogenates were quantified for doxo penetration via fluorimeter. Data represent mean ± SEM.
Laser treatment significantly increased parenchymal doxo compared to sham (n = 3 for each condition, t-test, *P < .01). (C) Timeline of in vivo preclinical
study to test LITT plus adjuvant doxo. (D) After orthotopic implantation of luciferase-expressing GL261 cells, BLI was performed on mice before a laser or
sham treatment (day 7) and after indicated treatments in the same mice (day 14). Representative BLI images are shown from 3 animals in each group (n = 5
for each condition). Control = sham treatment plus intravenous vehicle; doxo alone = sham treatment plus intravenous doxo; laser alone = laser treatment
plus intravenous vehicle. (E) Quantification of BLI images from animals treated as in D is shown. Laser plus doxo caused a significant decrease in tumor
burden compared to control or doxo alone (n = 5 in each condition, ANOVA, *P < .05). (F) Mice treated as in D were monitored for neurological deficit-free
survival (n = 8–12 for each condition). Whereas laser treatment alone showed a modest survival benefit compared to control or doxo (log-rank test with
Bonferroni, *P < .0001), laser plus doxorubicin (2 doses, 12 mg/kg on day 4 and 8 mg/kg on day 14 post-laser) substantially increased survival compared to
control, doxo, or laser alone (log-rank test with Bonferroni, **P < .0001, P < .0001, P < .004, respectively).
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pharmaceutical interventions may be considered for the
treatment of glioblastoma and raises the intriguing possibility that LITT may increase access of drugs to additional
brain pathologies. Further understanding of the specific
mechanisms by which LITT causes changes in BBB and
BTB properties is needed, as such information will provide
insight into how to optimize the timing of drug delivery
after LITT and, potentially, to augment LITT-induced BBB
effects.

Supplementary data are available at Neuro-Oncology
Advances online.
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early experimental studies in animal models explored
the general histopathological impact of LITT on normal
brain and brain tumors, there has been little investigation of fundamental characteristics of the LITT effect on
BBB/BTB permeability, such as molecular size threshold,
duration, mechanism of action, and therapeutic efficacy.28–31 Our in vivo results provide direct evidence that
the thermal effect of LITT disrupts the BBB and BTB at
a targeted location. We demonstrate that laser treatment
can greatly increase the amount of IgG that permeates
laser-treated brain and brain tumors, raising the possibility that LITT may increase the delivery, and therefore
efficacy, of therapeutic antibodies currently being used in
clinical trials.32,33
We also sought to identify the mechanisms by which
LITT alters BBB permeability. We discovered that at least
one mechanism of laser-enhanced BBB permeability
in vivo and in vitro occurs via tight junction disruption.
Earlier studies indicated that whole-body hyperthermia
(>40.0°C) alters glial and brain endothelial cell morphology.34 These studies, in conjunction with our in vitro
experiments (Figure 4D and E), suggest the BBB effects of
LITT operate through direct thermal effects on the endothelium. We also observed that, whereas control brain endothelial cells exhibit extremely low steady-state levels of
transcytotic vesicles, laser-treated brain demonstrated an
increased number of endothelial cell vesicles, suggesting
that LITT increases the rate of transcytosis (Figure 5). The
mechanisms by which endothelial cell transcytosis is inhibited in the brain are only beginning to become known.24
It will be of interest in future studies to determine if the
endocytic vesicles observed following laser treatment represent macropinocytosis, clathrin-dependent endocytosis,
or caveolae-mediated endocytosis.35–37 Gu et al.25,38 recently reported that vesicle formation and transcytosis are
actively suppressed in brain endothelial cells via a Mfsd2a
and caveolin-1-dependent mechanism. Although highly
speculative, these findings raise the intriguing hypothesis
that thermal energy may dysregulate Mfsd2a-dependent
processes to increase endothelial cell transcytosis.
Furthermore, it remains to be determined if secondary effects of LITT, such as the elaboration of cytokines or other
inflammatory mediators, might also contribute to both
LITT-induced transcytosis and/or endothelial tight junction
disruption.39
This study has several limitations, primarily inherent to
the use of a mouse animal model. Mice have different immunology, physiology, and potentially treatment response
compared to humans. Other limitations include use of a
thermocouple device, which provides temperature data
at only specific points around the laser (core and 1 mm
away), instead of MR thermometry (although MR thermometry is an indirect, calculated measure of temperature
and is therefore not as accurate as the direct temperature
measurements used in this study). There are also limitations associated with the tumor models used. GL261 elicits
a more robust immune reaction in mice than GBM does
in humans, and patient-derived xenografts (MGG8 line,
Figure 3G) are limited by the immunocompromised setting
in which they are implanted.
Our results suggest that combining transient BBB disruption via LITT with adjuvant antibody, biologic, or other
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